

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF THE SENATE

02 FEB -8 PM 3:00

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Aventis Pharma AG			
2. Address <input type="checkbox"/> Check if different than previously reported 801 Pennsylvania Avenue, NW, Suite 725			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20004			
4. Contact Name Eddie D. Evans		Telephone 202-898-3182	5. Senate ID 56838-
7. Client Name <input checked="" type="checkbox"/> Self		E-mail (optional)	6. House ID 351860

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30)  OR Year End (July 1-

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇨ Termination Date \_\_\_\_\_ 11. No Lobby

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>1.3M</u> Expenses (nearest \$)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description. <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 162(e) Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature \_\_\_\_\_

Printed Name and Title

LD-2 (REV. 6/98)



Registrant Name Aventis Pharma AG Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each c information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R.2330; Agriculture, Rural Development, Food and Drug Administration and rela Agencies Appropriations Act, 2002, all provisions relating to the reimportation prescription pharmaceuticals.

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Donald Zowader	
Eddie Evans	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA, headquartered in Strasburg, France is the parent company of Aveni Pharmaceuticals. Aventis Pharmaceuticals is interested because of the potent: negative effect this legislation could have on public health.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Form I.D-2 (Rev 6/98)

P:



Registrant Name Aventis Pharma AG Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each c information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 826, Improved Access to Osteoporosis Testing Act of 2001  
H.R. 1720, Improved Access to Osteoporosis Testing Act of 2001

All provisions relating to eliminating the cost sharing for high risk Medicare beneficiaries for BMD screenings.

17. House(s) of Congress and Federal agencies contacted  Check if None

Senate and House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Donald Zowader	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA, headquartered in Strasburg, France is the parent company of Aventi Pharmaceuticals. Aventis Pharmaceuticals is interested in this legislation bec it could lead to early detection of individuals with osteoporosis.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Form I.D-2 (Rev 6/98)

Pa



Registrant Name Aventis Pharma AG Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each c information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

S. 1789, Best Pharmaceuticals for Children Act, all provisions.

17. House(s) of Congress and Federal agencies contacted  Check if None

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Aventis SA, headquartered in Strasburg, France is the parent company of Aveni Pharmaceuticals. Avenits Pharmaceuticals is interested in the reauthorization this Act because it provides an incentive to manufacturers to conduct pediatri clinical trials.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Form I.D.-2 (Rev 6/98)

P:



Registrant Name Aventis Pharma AG Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific lobbying issues

S. 754, Drug Competition Act of 2001, all provisions.

17. House(s) of Congress and Federal agencies contacted

Check if None

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Judy Cook	
Eddie Evans	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Aventis SA, headquartered in Strasburg, France is the parent company of Aventis Pharmaceuticals. Aventis Pharmaceuticals is interested in ensuring that the objectives of this legislation are achieved and unintended consequences minimized.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Form I.D-2 (Rev 6/98)

Pa



Registrant Name Aventis Pharma AG Client Name \_\_\_\_\_

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Draft Medicare Drug Reimbursement legislation to change the way that drugs are reimbursed by Medicare Part B.

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Eddie Evans	
Judy Cook	

19. Interest of each foreign entity in the specific issues listed on line 16 above.  Check if None

Aventis SA, headquartered in Strasburg, France is the parent company of Aventis Pharmaceuticals. Aventis Pharmaceuticals is interested in this provision to ensure that the final reimbursement scheme is fair and equitable for all stakeholders.

Signature Eddie P. Evans Date February

Printed Name and Title Eddie D. Evans, VP, Federal Government Affairs

Form I.D-2 (Rev 6/98)

Page

